Reliable Sources of Historical Site Performance Data for Informed Feasibility Planning

Introduction: Why Historical Data Matters in Site Selection

Feasibility assessments based solely on investigator reputation or generic questionnaire responses are no longer sufficient. Regulatory expectations under ICH E6(R2) and growing emphasis on quality-by-design demand data-driven decisions—particularly when selecting or requalifying clinical trial sites. One of the most powerful tools in this regard is historical site performance data.

However, such data is fragmented across multiple systems, stakeholders, and documents. To effectively use performance history, sponsors and CROs must first identify and validate reliable sources. This article outlines the key repositories—both internal and external—that house performance-related insights critical to clinical site evaluation.

1. Clinical Trial Management System (CTMS)

Primary Source: Site activity, enrollment metrics, deviation records, visit schedules

The CTMS is the most comprehensive internal repository of site-level performance data. When properly maintained, it provides structured, longitudinal records across multiple studies. Common metrics extracted include:

• Actual vs. planned enrollment timelines
• Screen failure and dropout rates
• Site activation duration (contracting to SIV)
• Protocol deviation frequencies
• Monitoring visit outcomes and action item resolution

Data from the CTMS can be exported into scoring algorithms or dashboards to rank sites against key performance thresholds.

2. Electronic Data Capture (EDC) Systems

Use Case: Data entry timeliness, query resolution efficiency

EDC systems provide real-time, timestamped evidence of a site’s data management performance. Sponsors should extract:

• Average time to resolve queries
• Number of queries per subject
• Frequency of inconsistent or missing entries
• Instances of backdated or corrected entries (audit trail review)

These indicators contribute to evaluating data integrity and operational discipline at the site level.

3. Monitoring Visit Reports (MVRs)

Source: CRAs’ documented observations and findings

MVRs provide qualitative and narrative context to complement quantitative CTMS data. They reveal:

• Site staff engagement and responsiveness
• Issues with IP storage or informed consent practices
• Monitoring delays and follow-up challenges
• Facility conditions and documentation practices

Feasibility teams should review MVRs from at least the last 2–3 studies conducted by the site.

4. Audit and Inspection Reports

Internal audits: Conducted by QA departments

Regulatory inspections: Conducted by FDA, EMA, MHRA, CDSCO, etc.

These reports are essential to understand the site’s compliance history. Key data points include:

• Number of audits conducted and frequency
• Findings classification: critical, major, minor
• CAPA effectiveness and recurrence of issues
• Regulatory warning letters or Form 483 issuance

For public access, regulators like the FDA provide searchable inspection records via [FDA Inspection Database](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-database).

5. Trial Master File (TMF) and eTMF Systems

Documents Reviewed: Delegation logs, training records, IRB approvals, deviation logs

Sites with consistent TMF compliance typically demonstrate strong trial management systems. When reviewing TMFs:

• Check completeness and timeliness of submissions
• Evaluate site file organization and document version control
• Assess availability of GCP and protocol-specific training logs

eTMF metadata can also reveal submission patterns—frequent late uploads may suggest administrative inefficiencies.

6. Site Performance Dashboards (Sponsor-Created)

Many large sponsors build centralized dashboards that aggregate site metrics across studies. These may include:

• Site ranking based on custom KPIs
• Benchmarking across therapeutic areas
• Repeat participation history
• Real-time deviation and query alerts

These dashboards support feasibility reviews and can generate site profiles with graphical performance summaries.

7. CRO Reports and Vendor-Managed Portals

When feasibility and monitoring are outsourced, CROs often maintain site performance data in their proprietary systems. Sponsors should request:

• Study summary reports by site
• Aggregated site performance trends across portfolios
• Enrollment forecasting accuracy logs
• CRA-reported issues unresolved beyond timeline

Vendor qualification SOPs should include access to such performance data when selecting or renewing CRO partnerships.

8. External Clinical Trial Registries and Inspection Portals

These public databases can reveal past participation and regulatory scrutiny at global levels:

• ClinicalTrials.gov – Lists studies by site, sponsor, PI
• EU Clinical Trials Register – EU-based site and trial data
• CTRI (India) – Trial listings by Indian sites and ethics boards
• Japan PMDA RCT Portal – Site registrations and disclosures
• Canada Health Trial Database

While these don’t contain audit details, they reveal participation history, trial phases, and therapeutic experience.

9. Investigator CVs and Feasibility Questionnaires

Though often considered subjective, CVs and completed questionnaires provide context to objective data. Review:

• PI’s previous indications and study phases
• Training and GCP certifications
• Self-reported enrollment success and challenges

These should be cross-verified against actual performance data from CTMS and CRO portals.

Conclusion

Robust site selection and feasibility planning require a multi-source, cross-validated approach to historical performance data. By aggregating insights from internal systems (CTMS, EDC, TMF), monitoring reports, audits, and global registries, sponsors and CROs can develop objective, consistent, and inspection-ready criteria for site engagement. As clinical development becomes more digital, integrating these data streams will be critical not just for faster startup—but for trial success and regulatory compliance.

Evaluating Past Site Performance: A Key to Smarter Clinical Trial Feasibility

Introduction: Why Historical Site Performance Matters

In the competitive landscape of clinical trials, choosing the right sites can make or break a study. One of the most predictive indicators of future success is a site’s historical performance in prior trials. Regulators like the FDA and EMA expect sponsors and CROs to use past performance as part of risk-based site selection under ICH E6(R2) guidelines.

Evaluating site performance isn’t simply about how fast a site can enroll. It includes understanding past enrollment trends, protocol deviation rates, audit findings, data quality issues, and patient retention patterns. This article provides a detailed methodology for assessing historical site performance as part of a robust feasibility process, supported by real-world examples and performance dashboards.

Key Performance Indicators (KPIs) for Site History Evaluation

To evaluate a site’s past performance, sponsors should examine a mix of quantitative and qualitative KPIs. These include:

• Actual vs. projected enrollment rates
• Screen failure ratios and dropout rates
• Frequency and severity of protocol deviations
• Query resolution timelines and data quality metrics
• Audit findings (internal, sponsor, and regulatory)
• Inspection outcomes (e.g., FDA 483s, Warning Letters)
• Timeliness of regulatory and EC submissions
• Monitoring burden (e.g., number of follow-ups required)

These metrics should be reviewed for at least 3–5 previous trials, ideally within the same therapeutic area and trial phase.

Sources of Historical Site Performance Data

Collecting past performance data requires a blend of internal systems, external databases, and direct site engagement. Typical sources include:

• CTMS (Clinical Trial Management System): Site visit logs, enrollment data, deviation reports
• EDC Systems: Query logs, data entry timelines, SDV delays
• Monitoring Reports: CRA visit notes, risk indicators
• Trial Master File (TMF): Inspection reports, CAPAs, and audit summaries
• Regulatory Databases: Publicly available inspection databases like [FDA 483 Database](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-technical-guides/fda-inspection-database)
• WHO ICTRP or [ClinicalTrials.gov](https://clinicaltrials.gov): Used to identify prior studies at the site or by the PI

Sample Performance Scorecard Template

A standardized scorecard helps quantify site performance for comparative analysis.

Such tools allow sponsors to adopt objective, data-driven site selection methodologies.

Case Study: Impact of Historical Performance on Site Choice

In a global oncology trial, Sponsor X was selecting 40 sites across Europe and Asia. Site X1 had responded quickly to feasibility and had solid infrastructure. However, their CTMS record showed:

• 8 major protocol deviations in the last study
• 2 instances of delayed AE reporting
• 5 subject dropouts within the first 4 weeks

Despite strong initial feasibility responses, these historical indicators led the sponsor to deselect the site. Another site with moderate infrastructure but better historical KPIs was chosen instead, reducing overall trial risk.

How to Score and Benchmark Sites

Organizations can develop internal scoring systems based on historical metrics. A basic example includes:

• Enrollment performance: 30 points
• Protocol compliance: 30 points
• Data quality: 20 points
• Inspection/audit history: 20 points

Sites scoring above 80 may be pre-qualified. Those under 60 should be considered only with additional oversight or justification.

Integrating Performance Data into Feasibility Systems

To make site history actionable, integration into planning systems is essential:

• Link CTMS and feasibility dashboards for real-time performance scoring
• Use machine learning to predict high-risk sites based on historical patterns
• Tag underperforming sites with audit flags or CAPA requirements
• Centralize all prior audit and deviation data into the site master profile

Organizations using integrated platforms report faster site selection, improved regulatory compliance, and better patient retention.

Regulatory Expectations for Documenting Site Selection

Per ICH E6(R2), sponsors must “select qualified investigators and sites” and provide documentation to justify their selection. Key expectations include:

• Documented rationale for site inclusion or exclusion
• Evidence of performance metrics and monitoring trends
• Identification and mitigation of prior compliance issues
• Storage of evaluations in the TMF for inspection purposes

EMA inspectors, for example, may request justification for selecting a site with prior inspection findings or underperformance, especially if not mitigated by CAPAs.

Best Practices for Historical Site Review

• Review minimum 3 prior trials within the last 5 years
• Include PI-specific metrics as well as site-wide data
• Engage QA to review audit and CAPA history
• Cross-check with public databases (e.g., FDA 483s, EU CTR)
• Use scorecards to support selection meetings and approvals
• Archive all scoring and rationale documents in the TMF

Conclusion

Evaluating a site’s past performance is a critical component of modern, risk-based clinical trial feasibility. It ensures that decisions are informed, justified, and aligned with regulatory expectations. Sponsors and CROs that adopt structured performance reviews—integrated with feasibility workflows and planning systems—can reduce trial risks, enhance subject safety, and accelerate startup timelines. As trials become more complex and globalized, historical data will remain a core strategic asset in clinical operations planning.